Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7475009 | 0.88 | F2 (0.47) | F2KMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL17232477 | 0.84 | L3MBTL1 (0.50) | F2KMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL6926426 | 0.84 | F2 (0.45) | F2KMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL1197438 | 0.84 | CRHBP (0.44) | F2KMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL6931538 | 0.82 | KMT2A (0.48) | F2KMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL12306340 | 0.81 | CYP1A2 (0.38) | F2KMT2AMEN1ALDH1A1 | |
| SCHEMBL6930547 | 0.81 | F2 (0.42) | F2KMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL14452034 | 0.81 | F2 (0.50) | F2KMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL17229307 | 0.81 | F2 (0.50) | F2KMT2AMEN1APOBEC3AAPOBEC3G | |
| SCHEMBL30640530 | 0.80 | TPH1 (0.40) | F2KMT2AMEN1CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2002022584-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | TFPI, SERPINC1, PLAT | F2 5/4885KMT2A 3473/4885MEN1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.